Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
58.17 BRL | +23.03% | +3.56% | -3.84% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 31.58 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.84% | 78.43B | - | ||
+24.87% | 8.99B | B- | ||
+24.38% | 3.72B | B- | ||
+0.14% | 3.19B | B- | ||
+12.67% | 1.67B | - | ||
-2.93% | 1.3B | - | ||
-26.65% | 1.24B | B | ||
-28.50% | 1.22B | C- | ||
-19.43% | 1.07B | - | ||
-9.88% | 968M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ZTS Stock
- Z1TS34 Stock
- Ratings Zoetis Inc.